Argentine bioethics research has exposed critical gaps in genetic carrier screening for egg and sperm donors, revealing that current panels lack national genomic reference data and may reinforce bias by classifying human traits as avoidable conditions.
Researcher Natacha Salomé Lima of CONICET examined consent forms from one fertility clinic, one gamete bank, and three genetic testing companies, finding that donors often sign documents without fully grasping the health implications for themselves and their families, according to Diario Río Negro | Periodismo en la Patagonia.
Asymmetry in Risk and Benefit
Lima identified a structural asymmetry: recipients and future children gain actionable reproductive data, while donors bear the burden of learning unexpected health information without guaranteed clinical follow-up.
Carrier screening detects pathogenic variants in autosomal recessive or X-linked genes; if both genetic contributors carry a variant in the same gene, the offspring faces a 25 percent risk of inheriting the condition. However, a negative panel result reduces— but does not eliminate— residual risk.
Missing National Genomic Reference
Argentina lacks a national reference genome and reliable population-level allele frequency data. This absence complicates variant interpretation, making it difficult to distinguish pathogenic mutations from benign polymorphisms specific to Argentine ancestries. Without this baseline, laboratories cannot optimally curate which genes to include in expanded carrier panels, potentially leading to false positives or missed diagnoses relevant to local demographics.
“The absence of a national genomic reference means we are interpreting variants against databases that do not represent our population. This creates a diagnostic blind spot.”
Consent Forms Fall Short of Understanding
The study analyzed informed consent documents and found they frequently use dense technical language. Signing a form does not equate to comprehending concepts like variable expressivity, incomplete penetrance, or the possibility of incidental findings revealing the donor’s own disease risk. Lima argued that mandatory pre- and post-test genetic counseling is essential to bridge this gap, yet it is not currently standardized across all Argentine fertility centers.
The Argentine Society of Reproductive Medicine (SAMER) consensus currently recommends karyotyping—analysis of chromosome number and structure—as the baseline genetic assessment for donors. Expanded carrier screening panels, which sequence hundreds of genes, remain optional. This creates a two-tier system where access to comprehensive genetic data depends on the clinic’s protocols and the recipient’s ability to pay for additional testing.
Carrier Screening Does Not Diagnose Donor Disease
- Carrier screening identifies if a donor carries a gene for a recessive disorder; it does not diagnose disease in the donor.
- Current Argentine panels lack a local reference genome, reducing accuracy for specific populations.
- Donors need dedicated genetic counseling—not just a signature on a form—to understand results affecting their health and relatives.
Bias in Panel Composition
Lima warned that expansive panels risk pathologizing human variation. By including genes associated with non-life-threatening traits or adult-onset conditions with variable penetrance, screening frameworks may implicitly designate certain phenotypes as “undesirable,” echoing eugenic undertones. The ethical distinction between preventing severe childhood disease and selecting against disability or difference remains unresolved in current regulatory frameworks.
Unlike mitochondrial donation regulations in the UK overseen by the HFEA, or the FDA’s guidance on donor eligibility in the US, Argentina has no federal mandate for expanded carrier screening in gamete donation.
The National Administration of Drugs, Foods and Medical Devices (ANMAT) regulates the assays as in vitro diagnostics, but clinical implementation guidelines fall to professional societies. Lima's research shows the urgency for a national biobank and reference genome project to standardize variant classification.
Established by a 1958 decree with Nobel laureate Bernardo A. Houssay as its first director, CONICET coordinates most of Argentina’s university and institute research. Governed by a board independent from the federal government, it employs about 6,500 researchers and 2,500 technicians while funding 8,500 doctoral and post-doctoral scholars. In 2025, the Scimago Institutions Ranking named it the top Latin American government research institution and 125th worldwide.
“We cannot keep importing reference data from European or North American cohorts. We need an Argentine genome to practice precision medicine equitably.”
| Genetic Assessment | Current SAMER Recommendation | Scope | Primary Limitation |
|---|---|---|---|
| Karyotype | Mandatory | Chromosomal number/structure (e.g., translocations, aneuploidy) | Misses single-gene (Mendelian) disorders |
| Expanded Carrier Screening (ECS) | Optional / Clinic-dependent | Hundreds of genes (recessive & X-linked) | Variant interpretation challenges without national reference data; incidental findings |
References
- Fundación Dr. Jaime Roca. Premio Anual de Bioética 2026 Distinctions.
- Sociedad Argentina de Medicina Reproductiva (SAMER). Consenso sobre estudios genéticos en donantes de gametos.
- CONICET. Research profile: Natacha Salomé Lima, Bioethics and Assisted Reproduction.